5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
Iyer
L
L
Department of Medicine, University of Chicago, Illinois, USA.
Ratain
M J
MJ
D000284:Administration, Oral; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D042943:Dihydrouracil Dehydrogenase (NADP); D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*; D006801:Humans; D007262:Infusions, Intravenous; D010088:Oxidoreductases / Q000037:antagonists & inhibitors / Q000235:genetics; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil